|1.||Kloog, Yoel: 5 articles (11/2008 - 05/2002)|
|2.||Goldberg, Liat: 3 articles (11/2008 - 08/2006)|
|3.||Jaggi, Amteshwar Singh: 2 articles (03/2013 - 05/2012)|
|4.||Singh, Nirmal: 2 articles (03/2013 - 05/2012)|
|5.||Kloog, Y: 2 articles (01/2006 - 08/2000)|
|6.||Mardor, Yael: 1 article (11/2008)|
|7.||Daniels, Dianne: 1 article (11/2008)|
|8.||Ocherashvilli, Aharon: 1 article (11/2008)|
|9.||Tamar, Gregory: 1 article (11/2008)|
|10.||Last, David: 1 article (11/2008)|
01/01/2003 - "Daily administration of 10, 20, or 40 mg per kg of farnesyl thiosalicylic acid resulted in a concentration-dependent reduction in tumor growth, with growth inhibition reaching a mean value of 45+/-7%, at the highest concentration. "
01/01/2003 - "The combination of farnesyl thiosalicylic acid (10 mg per kg per day) and dacarbazine (80 mg per kg per day) resulted in a significant reduction of 56%+/-9%, in mean tumor growth. "
01/01/2003 - "Farnesyl thiosalicylic acid, a novel Ras inhibitor, dislodges Ras proteins from the cell membrane, leading to inhibition of cell transformation and tumor growth. "
|2.||Neuralgia (Stump Neuralgia)
03/01/2013 - "The present study was designed to investigate the analgesic potential of farnesyl thiosalicylic acid, a novel Ras inhibitor, and GW 5074, a selective c-Raf1 inhibitor, in chronic constriction-induced injury (CCI)-induced peripheral neuropathic pain. "
03/01/2013 - "The analgesic effects of farnesyl thiosalicylic acid and GW 5074 in CCI model suggests that pharmacological inhibition of Ras and c-Raf-1 signaling may be potentially useful for managing neuropathic pain."
03/01/2013 - "Intrathecal delivery of farnesyl thiosalicylic acid and GW 5074 attenuates hyperalgesia and allodynia in chronic constriction injury-induced neuropathic pain in rats."
05/01/2012 - "The present study investigates the analgesic potential of farnesyl thiosalicylic acid, a novel Ras inhibitor, and GW 5074, a selective c-Raf1 inhibitor, in vincristine-induced neuropathic pain. "
05/01/2012 - "The analgesic effects of farnesyl thiosalicylic acid and GW 5074 in vincristine model suggests that pharmacological inhibition of Ras and c-Raf-1 signalling may be potentially useful for managing neuropathic pain."
|3.||Melanoma (Melanoma, Malignant)
01/01/2003 - "Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo."
04/01/2002 - "Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects."
01/01/2003 - "Given the observed preclinical treatment responses and the low toxicity, our results support the notion that farnesyl thiosalicylic acid in combination with dacarbazine may qualify as a rational treatment approach for human melanoma."
01/01/2003 - "In this study we evaluated the effect of farnesyl thiosalicylic acid treatment on established human melanoma xenografts grown in mice with severe combined immunodeficiency as well as the chemosensitizing effect of farnesyl thiosalicylic acid in combination with dacarbazine. "
|4.||Glioblastoma (Glioblastoma Multiforme)
12/15/2006 - "Here, we show that the Ras inhibitor S-trans, trans-farnesyl thiosalicylic acid (FTS) can avert the transformation of human glioblastoma multiforme cells by inhibiting both their migration and their anchorage-independent proliferation. "
08/01/2006 - "Recent studies showed that the Ras inhibitor farnesyl thiosalicylic acid downregulates the transcription factor hypoxia-inducible factor-1alpha, causing shutdown of glycolysis in U87 glioblastoma cells. "
|5.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|2.||5- iodo- 3- ((3,5- dibromo- 4- hydroxyphenyl)methylene)- 2- indolinone
|4.||Transcription Factors (Transcription Factor)
|9.||5,8,11,14-Eicosatetraynoic Acid (5,8,11,14 Eicosatetraynoic Acid)
|10.||Guanosine Triphosphate (GTP)
|1.||Heterologous Transplantation (Xenotransplantation)